WASHINGTON, D.C. (AP) — Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.
Search Results - stltoday.com, St. Louis Post-Dispatch: Business
Fri, 12/19/2014 - 1:35pm
WASHINGTON, D.C. (AP) — Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.